NEW YORK – Laboratory Corporation of America announced Monday an exclusive licensing agreement with Genfit to commercialize Genfit's NIS4 technology for patients with non-alcoholic steatohepatitis (NASH).
NEW YORK – Laboratory Corporation of America announced Monday an exclusive licensing agreement with Genfit to commercialize Genfit's NIS4 technology for patients with non-alcoholic steatohepatitis (NASH).
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.